UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 15

 

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 001-38551

 

 

BIONTECH US INC.

(Exact name of registrant as specified in its charter)

 

 

40 Erie St., Suite 110

Cambridge, MA 02139

(617) 337-4701

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

None

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

Rule 12g-4(a)(1)

   

Rule 12g-4(a)(2)

   

Rule 12h-3(b)(1)(i)

   

Rule 12h-3(b)(1)(ii)

   

Rule 15d-6

   

Approximate number of holders of record as of the certification or notice date: One

Pursuant to the requirements of the Securities Exchange Act of 1934, BioNTech US Inc. (f/k/a Neon Therapeutics, Inc.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date: May 18, 2020

 

BioNTech US Inc. (f/k/a Neon Therapeutics, Inc.)
By:  

/s/ Richard Gaynor

Name:   Richard Gaynor
Title:   President

 

 

 

Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Neon Therapeutics Charts.
Neon Therapeutics (NASDAQ:NTGN)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Neon Therapeutics Charts.